Adaptimmune Therapeutics (NASDAQ:ADAP) Stock Crosses Below 50-Day Moving Average – Should You Sell?

Adaptimmune Therapeutics plc (NASDAQ:ADAP) shares crossed below its 50 day moving average during trading on Monday . The stock has a 50 day moving average of $0.60 and traded as low as $0.57. Adaptimmune Therapeutics shares last traded at $0.60, with a volume of 613,593 shares trading hands.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. HC Wainwright reduced their price target on Adaptimmune Therapeutics from $4.00 to $3.50 and set a “buy” rating for the company in a report on Thursday, November 14th. Mizuho reduced their price target on Adaptimmune Therapeutics from $3.00 to $1.50 and set an “outperform” rating for the company in a report on Wednesday, November 27th. StockNews.com downgraded Adaptimmune Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, November 14th. Finally, Guggenheim reduced their price target on Adaptimmune Therapeutics from $4.00 to $3.00 and set a “buy” rating for the company in a report on Friday, November 15th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $2.79.

Adaptimmune Therapeutics Trading Down 3.1 %

The company has a debt-to-equity ratio of 0.62, a quick ratio of 3.82 and a current ratio of 3.85. The business has a fifty day simple moving average of $0.60 and a 200 day simple moving average of $0.83. The company has a market cap of $153.79 million, a P/E ratio of -2.73 and a beta of 2.42.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of ADAP. Fullcircle Wealth LLC bought a new position in Adaptimmune Therapeutics during the 3rd quarter worth approximately $33,000. Vontobel Holding Ltd. raised its position in shares of Adaptimmune Therapeutics by 230.8% during the 3rd quarter. Vontobel Holding Ltd. now owns 43,000 shares of the biotechnology company’s stock worth $41,000 after purchasing an additional 30,000 shares during the period. GSA Capital Partners LLP acquired a new stake in shares of Adaptimmune Therapeutics during the 3rd quarter worth approximately $95,000. Virtu Financial LLC raised its position in shares of Adaptimmune Therapeutics by 27.5% during the 3rd quarter. Virtu Financial LLC now owns 101,008 shares of the biotechnology company’s stock worth $96,000 after purchasing an additional 21,769 shares during the period. Finally, Jane Street Group LLC raised its position in shares of Adaptimmune Therapeutics by 130.4% during the 3rd quarter. Jane Street Group LLC now owns 174,157 shares of the biotechnology company’s stock worth $166,000 after purchasing an additional 98,581 shares during the period. Institutional investors own 31.37% of the company’s stock.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.